Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of dipraglurant in PD patients with dyskinesia
NCT05116813Phase 3Terminated
- Sponsor
- Addex Therapeutics Ltd
- Start
- Oct 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dipraglurant in levodopa-induced dyskinesia (LID), sponsored by Addex Therapeutics Ltd. Primary endpoint: Incidence of adverse events at 52 weeks. Started Oct 2021; status: terminated.
02
Drugs
dipraglurant
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT05116813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05116813.